Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer

References

• Cancer Registry of Norway. Cancer in Norway 2000. 2002.
   Google Scholar
• Dahl O, Kardamakis D, Lind B, Rosenwald JC. Current status of conformal radiotherapy. Acta Oncol 1996; 35(Suppl 8)41–57
   PubMed Web of Science ®Google Scholar
• Vicini FA, Abner A, Baglan KL, Kestin LL, Martinez AA. Defining a dose-response relationship with radiotherapy for prostate cancer: Is more really better?. Int J Radiat Oncol Biol Phys 2001; 51(5)1200–8
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166(3)876–81
   PubMed Web of Science ®Google Scholar
• Horwich A, Wynne C, Nahum A, Swindell W, Dearnaley DP. Conformal radiotherapy at the Royal Marsden Hospital (UK). Int J Radiat Biol 1994; 65(1)117–22
   PubMed Web of Science ®Google Scholar
• Lilleby W, Dale E, Olsen DR, Gude U, Fossa SD. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose. Acta Oncol 2003; 42(1)10–4
   PubMed Web of Science ®Google Scholar
• Shearer RJ, Davies JH, Gelister JS, Dearnaley DP. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 1992; 69(5)521–4
   PubMedGoogle Scholar
• TNM classification of malignant tumours. 4th ed., Geneva, Schweiz: International Union Against Cancer; 1992.
   Google Scholar
• Mostofi FK, Sesterhenn IA, Sobin LH. Histological typing of prostate tumours. World Health Organization, Geneva 1980
   Google Scholar
• Mellinger GT, Gleason D, Bailar J. The histology and prognosis of prostatic cancer. J Urology 1967; 97: 331–8
   PubMed Web of Science ®Google Scholar
• Van der Kwast TH, Roobol MJ, Wildhagen MF, Martikainen PM, Maatnanen L, Pihl CG, et al. Consistency of prostate cancer grading results in screened populations across Europe. BJU Int 2003; 92(Suppl 2)88–91
   PubMed Web of Science ®Google Scholar
• Karlsdottir A, Johannessen DC, Muren LP, Wentzel-Larsen T, Dahl O. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 2004; 71(1)43–53
   PubMed Web of Science ®Google Scholar
• Pickles T, Kim-Sing C, Morris WJ, Tyldesley S, Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 2003; 57(1)11–8
   PubMed Web of Science ®Google Scholar
• Kestin LL, Vicini FA, Martinez AA. Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys 2002; 53(2)304–15
   PubMed Web of Science ®Google Scholar
• Altman D. Practical statistics for medical research. Chapman and Hall, London and New York 1991; 611
   Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280(11)969–74
   PubMed Web of Science ®Google Scholar
• Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4(4)233–41
   PubMed Web of Science ®Google Scholar
• Parker CC, Dearnaley DP. Radical radiotherapy for prostate cancer. Cancer Treat Rev 2003; 29(3)161–9
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Chen M-H, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 2002; 54(2)436–41
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carrol PR. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 2004; 22(11)2141–9
   PubMed Web of Science ®Google Scholar
• Draisma G, Boer R, Otto SJ, Van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95(12)868–78
   PubMed Web of Science ®Google Scholar
• Lujan M, Paez A, Miravalles E, Fernandez I, Llanes L, Berenguer. A prostate cancer detection is also relevant in low prostate specific antigen ranges. Eur Urol 2004; 45(2)155–9
   PubMed Web of Science ®Google Scholar
• Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004; 100(3)538–43
   PubMed Web of Science ®Google Scholar
• Parker C. Active surveillance: Towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004; 5(2)101–6
   PubMed Web of Science ®Google Scholar
• Borre M, Nerstrom B, Overgaard J. The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer 1997; 80(5)917–28
   PubMed Web of Science ®Google Scholar
• Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, et al. A randomised comparison of bicalutamide (‘Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol 2002; 42(3)204–11
   PubMed Web of Science ®Google Scholar
• Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347(11)781–9
   PubMed Web of Science ®Google Scholar
• Douglas TH, McLeod DG, Mostofi FK, Mooneyhan R, Connelly R, Moul JW, et al. Prostate-specific antigen-detected prostate cancer (stage T1c): An analysis of whole-mount prostatectomy specimens. Prostate 1997; 32(1)59–64
   PubMed Web of Science ®Google Scholar
• Hanks GE, Hanlon AL, Pinover WH, al-Saleem TI, Schultheiss TE. Radiation therapy as treatment for stage T1c prostate cancers. World J Urol 1997; 15(6)369–72
   PubMed Web of Science ®Google Scholar
• Pound CR, Walsh PC, Epstein JI, Chan DW, Partin AW. Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World J Urol 1997; 15(6)373–7
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Buchsbaum JC, Patel C, Elshatkh M, Reddy CA, Zippe C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 2002; 52(3)704–11
   PubMed Web of Science ®Google Scholar
• Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000; 48(3)629–33
   PubMed Web of Science ®Google Scholar
• Vicini FA, Kestin LL, Martinez AA. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 2000; 88(10)2305–18
   PubMed Web of Science ®Google Scholar
• Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57(1)19–23
   PubMed Web of Science ®Google Scholar
• Hoffelt SC, Marshall LM, Garzotto M, Hung A, Holland J, Beer TM. A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 57(1)29–32
   PubMed Web of Science ®Google Scholar
• Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate-specific antigen era: What should we expect?. Cancer 2004; 100(6)1283–92
   PubMed Web of Science ®Google Scholar
• Duchesne GM. Radiation for prostate cancer. Lancet Oncol 2001; 2(2)73–81
   PubMed Web of Science ®Google Scholar
• Fossa SD, Lilleby W, Waehre H, Berner A, Torlakovic G, Paus C, et al. Definitive radiotherapy of prostate cancer: The possible role of staging lymphadenectomy. Int J Radiat Oncol Biol Phys 2003; 57(1)33–41
   PubMed Web of Science ®Google Scholar
• Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44(4)809–19
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58(1)25–33
   PubMed Web of Science ®Google Scholar
• Bergstrom P, Lofroth PO, Widmark A. High-precision conformal radiotherapy (HPCRT) of prostate cancer–a new technique for exact positioning of the prostate at the time of treatment. Int J Radiat Oncol Biol Phys 1998; 42(2)305–11
   PubMed Web of Science ®Google Scholar
• Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355(9214):1491–8.
   Google Scholar
• Bolla M, Collette L, Blank L, Warde P, Dubors JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase lll randomised trial. Lancet 2002; 360: 103–8
   PubMed Web of Science ®Google Scholar
• Kupelian PA. External beam radiation therapy: Role of androgen deprivation. World J Urol 2003; 21(4)190–9
   PubMed Web of Science ®Google Scholar
• Gottschalk AR, Roach M 3rd. The use of hormonal therapy with radiotherapy for prostate cancer: Analysis of prospective randomised trials. Br J Cancer 2004; 90(5)950–4
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292(7)821–7
   PubMed Web of Science ®Google Scholar
• Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?. Int J Radiat Oncol Biol Phys 2003; 57(2)377–83
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50(5)1243–52
   PubMed Web of Science ®Google Scholar
• Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Radiation therapy dose escalation for prostate cancer: A rationale for IMRT. World J Urol 2003; 21(4)200–8
   PubMed Web of Science ®Google Scholar
• Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53(5)1097–105
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005; 92(3)488–98
   PubMed Web of Science ®Google Scholar
• Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43(4)316–81
   PubMed Web of Science ®Google Scholar
• DeWeese TL. Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: The new standard?. JAMA 2004; 292(7)864–6
   PubMed Web of Science ®Google Scholar